Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of lewy body-associated dementias

Journal of Alzheimer's Disease

Volumn 26, Issue 1, 2011, Pages 171-179

  Maetzler, Walter ^a,b,c   Berg, Daniela ^a,b   Synofzik, Matthis ^a,b   Brockmann, Kathrin ^a,b   Godau, Jana ^a,b   Melms, Arthur ^a   Gasser, Thomas ^a,b   Hörnig, Stephanie ^d   Langkamp, Markus ^e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d GMBU EV   (Germany)

^e Mediagnost   (Germany)

Author keywords

Astrocytes; autoantibodies; dementia with Lewy bodies; glial cells; Lewy body disease; oligodendrocytes; Parkinson's disease dementia

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AUTOANTIBODY; BIOLOGICAL MARKER; CELL ANTIGEN; GLIAL DERIVED ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEURAL DERIVED ANTIGEN; PROTEIN S100B; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; ASTROCYTE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; GLIA CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NERVE CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TAU ASSOCIATED DEMENTIA;

EID: 80052850843     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110221     Document Type: Article

References (42)

1. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nuss-baum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812-819. (Pubitemid 46568532)
2. Monahan AJ, Warren M, Carvey PM (2008) Neuroinflamma-tion and peripheral immune infiltrationinParkinson's disease: an autoimmune hypothesis. Cell Transplant 17, 363-372. (Pubitemid 351717339)
3. Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 Suppl 3, S49-S58; discussion S58-S60.
4. Mackenzie IR (2000) Activated microglia in dementia with Lewy bodies. Neurology 55, 132-134.
5. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19, 312-318. (Pubitemid 26349059)
6. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128, 2665-2674. (Pubitemid 41552950)
7. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42, 781-785.
8. Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ, Compston DA, Barker RA, Sawcer SJ, Goris A (2010) Association of the human leucocyte antigen region with susceptibility toParkinson's disease.J Neurol Neurosurg Psychiatry 81, 890-891.
9. Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y (2001) Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 58, 1580-1583. (Pubitemid 32963221)
10. Bas J, Calopa M, Mestre M, Mollevi DG, Cutillas B, Ambrosio S, Buendia E (2001) Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 113, 146-152. (Pubitemid 32008680)
11. Carvey PM, McRae A, Lint TF, Ptak LR, Lo ES, Goetz CG, Klawans HL (1991) The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology 41, 53-58; discussion 59-60.
12. Rowe DB, Le W, Smith RG, Appel SH (1998) Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 53, 551-558. (Pubitemid 28380796)
13. Chen S, Le WD, Xie WJ, Alexianu ME, Engelhardt JI, Siklos L, Appel SH (1998) Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 55, 1075-1080. (Pubitemid 28367232)
14. Defazio G, Dal Toso R, Benvegnu D, Minozzi MC, Cananzi AR, Leon A (1994) Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res 633, 206-212. (Pubitemid 24021263)
15. Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y, Messer A, Sierks MR (2004) Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43, 2871-2878. (Pubitemid 38327818)
16. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeor-giou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL (2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101, 749-756. (Pubitemid 46633311)
17. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57, 801-805. (Pubitemid 32845498)
18. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31, 175-193.
19. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Taka-hashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 99, 14-20. (Pubitemid 30093433)
20. Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jakala P, Beyreuther K, Masters CL, Li QX (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 76, 87-96. (Pubitemid 32044371)
21. Gibb WR, Lees AJ (1988) Acomparisonofclinical and pathological features of young-and old-onset Parkinson's disease. Neurology 38, 1402-1406.
22. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
24. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58, 1803-1809. (Pubitemid 33044246)
25. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Mas-deu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260. (Pubitemid 23060253)
26. Maetzler W, Schmid SP, Wurster I, Liepelt I, Gaenslen A, Gasser T, Berg D (2011) Reduced but not oxidized cere-brospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 26, 176-181.
27. Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, Huber H, Brockmann K, Gasser T, Berg D, Melms A (2010) The CST3BBgenotype and low cystatin Ccerebrospinalfluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 19, 937-942.
28. Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA (2010) Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods 187, 263-269.
29. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ (1998) Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 785, 195-206. (Pubitemid 28179382)
30. Langkamp M, Hornig SC, Hornig JB, Kirschner M, Pridzun L, Kornhuber ME (2009) Detection of myelin autoantibod-ies: evaluation of an assay system for diagnosis of multiple sclerosis in differentiation from other central nervous system diseases. Clin Chem Lab Med 47, 1395-1400.
31. Gao HM, Liu B, Zhang W, Hong JS (2003) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24, 395-401. (Pubitemid 36952555)
32. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3, e1376.
33. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD (2005) 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 22, 1158-1168. (Pubitemid 41395380)
34. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM (2007) TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 26, 36-46. (Pubitemid 46437443)
35. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
36. Farrall AJ, Wardlaw JM (2009) Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 30, 337-352.
37. Racette BA, Good L, Antenor JA, McGee-Minnich L, Moer-lein SM, Videen TO, Perlmutter JS (2006) [18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies. Am J Med Genet B Neuropsychiatr Genet 141B, 245-249.
38. Menge T, von Budingen HC, Lalive PH, Genain CP (2007) Relevant antibody subsets against MOG recognize confor-mational epitopes exclusively exposed in solid-phase ELISA. Eur J Immunol 37, 3229-3239. (Pubitemid 350131301)
39. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE (2005) Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 280, 17458-17463. (Pubitemid 41389217)
40. Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, Hynan L, German D, Kodadek T (2011) Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 144, 132-142.
41. Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA (2009) Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Abeta in plasma of patients with Alzheimer's disease. Neuro-biol Aging, doi:10.1016/j.neurobiolaging.2009.08.011.
42. Szabo P, Relkin N, Weksler ME (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7, 415-420.